Resolve Stroke is honored to be officially selected for the 2025 Prix Galien France in the Medtech & Digital Solutions category. This prestigious nomination highlights the impact and potential of our ultrasound-based neuroimaging technology to advance patient care. We thank the Prix Galien jury for recognizing our commitment to innovation in healthcare.

We are proud to announce that the RS-NeuroMarkers project has been selected by the European Innovation Council for a prestigious EIC Transition Grant. This €2.5M grant recognizes our mission to advance point-of-care neuroimaging, making brain monitoring more accessible through ultrasound technology. With RS-NeuroMarkers, we will integrate clinically validated brain biomarkers into our software engine, helping clinicians detect and monitor cerebral pathologies directly at the bedside.

First results from the collaboration between CHU Caen Normandie and Resolve Stroke officially presented at the SFAR meeting (French Society of Anaesthesia and Intensive Care), sparking great interest within the community.

Resolve Stroke has enrolled the first patients in a groundbreaking clinical trial using its #SYLVER platform to evaluate transcranial ultrasound data for detecting cerebral hypoperfusion in neurocritical care units. This significant milestone brings us closer to revolutionizing the application of ultrasound in neurology, much like the transformative journey of cardiac ultrasound years ago.